TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Changes in the Adjusted Number of Pumps in the Balloon Analogue Risk Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to psoriatic arthritis treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased intensity of IPH levels measured by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sorafenib exposure (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sorafenib peak plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sorafenib N-oxide exposure (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sorafenib N-oxide peak plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Light-intensity Physical Activity at Work
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Change in Sitting Time at Work
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Degree of pain provoked by catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in response times from session 1 to session 8 for correct and incongruent trials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in number of total commission errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in number of total omission errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Radiological healing and stability of the osteotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of social disconnectedness
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Number of Episodes of Severe Hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time Spent With Glucose <54 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Indices of Glucose Control: Time Spent in Glucose Ranges by Continuous Glucose Monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in weight from baseline to week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall Survival
Endpoint domain: Mortality/survival
Primary endpoint: Best Correct Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular Anatomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electroretinography Response (ERG Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in levels of blood biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of pulmonary exacerbations requiring antibiotic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of Participants Free of Biopsy-proven Rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PICC-related Venous Thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Changes in Right Ventricular Ejection Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of delirium/neurocognitive impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in neuroaxonal injury biomarker levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurocognitive 3-months outcome
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Clinician Administered PTSD Score (CAPS-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area under the plasma activity-time curve (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration of the factor VII activity (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cardiovagal Autonomic Dysfunction (CAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rescue dose of analgesic
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Brain Response to Food Imagery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Hunger Rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: development of brain lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With Change of Treated Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sleep efficiency (%)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Average AF burden in minutes per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Persistent AF free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Carotid plaque stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: freedom of ventricular arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Human Irisin (ng/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone specific alkaline phosphatase (IU/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: postoperative X-rays - Lane and Sandhu radiological scoring system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Immediate Reportable Events (IREs)
Endpoint domain: Adverse events/effects
Primary endpoint: Hunger and satiety assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain and anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in beliefs on how well the treatment might work
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Patient Reported Outcomes Measurement Information System-29 scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of Patients With a Diagnosis of Gestational Diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Histological markers of tumor angiogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tumor response to treatment based on WHO criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: odds ratios for exposures to environmental contaminants related to childhood leukemia
Endpoint domain: Mortality/survival
Primary endpoint: Mouth feel
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Appearance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Expected satiety
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: echographic follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in ZANarini Rating Scale for Borderline Personality Disorder Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical performance of aged ENTact™ Septal Staples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postsurgical change in bleeding patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postsurgical change in patient satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of respiratory complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Substance Use Frequency
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Treatment Failure (Unfavorable Outcome)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Bodily Pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change from baseline of muscle tone of the upper limb muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change from baseline of Basic motor abilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Preload Phase Duration (PLD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Glycemic variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute bioavailability of Subcutaneous administration of metoclopramide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of endometrial cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Hematopoietic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Lung Cancer Risk
Endpoint domain: Mortality/survival
Primary endpoint: Patient Satisfaction With Decision and Process
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of intraoperative air embolism
Endpoint domain: Adverse events/effects
Primary endpoint: Change in EEG power of alpha brainwaves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pathological Complete Response (pCR) Rate at the Time of Surgery - All Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological Complete Response (pCR) Rate at the Time of Surgery - PIK3CA Wild Type (WT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological Complete Response (pCR) Rate at the Time of Surgery - PIK3CA Mutant (MT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of paraesthesia during catheter insertion
Endpoint domain: Adverse events/effects
Primary endpoint: total incidence rate of digestive tract related adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Change in NT-proBNP from baseline to 16 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response rate by RECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Melatonin stability in human milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence rates of sexually transmitted infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Average Time to completion of obstacle path
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Number of Positive IPMN Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Staining Intensity After Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Post operative residual tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Major pathologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Continued Access to Atezolizumab-Based Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: subject reported pain level
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of Participants With Mitral Valve Regurgitation Severity ≤2+ at 30 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of Major Adverse Events (MAE) at 30 Days
Endpoint domain: Adverse events/effects
Primary endpoint: Number of days exceeded recommended drinking limits
Endpoint domain: Adverse events/effects
Primary endpoint: Total apnea time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in quality of life with Syncope Functional Status Questionnaire (SFSQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in quality of life with Short Form - 36 (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of number of syncopes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parenting style
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Number of participants with adverse events or adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of colorectal neoplasms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Risk of early onset Group B Streptococcus disease
Endpoint domain: Mortality/survival
Primary endpoint: Complete response (no vomiting, no retching, no rescue therapy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Air leak cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum-tolerated dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitamin A dose achieving upper quartile level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Any Adverse Events (AEs) Within 1 Month After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Any Serious Adverse Events (SAEs) Within 6 Months After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Any Newly Diagnosed Chronic Medical Conditions (NDCMCs) Within 6 Months After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Change in subjective effects measured with Biphasic alcohol effects scale (BAES)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in psychomotor vigilance task (PVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Reported Adequate Pain Relief at Baseline
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants Who Reported Adequate Pain Relief at Month 12
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum Percent Change From Baseline in MDS-UPDRS Part III
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Electrocardiogram (ECG) That Met Categorical Criteria for Concern (Increase From Baseline)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Administration of analgesic drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total bipolar electrogram amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of serum rabies virus neutralizing antibodies to protective levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean concentration (GMC) of serum rabies virus neutralizing antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Positive seroconversion rate of serum rabies virus neutralizing antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Gait Abnormalities Observed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validated 7-day point prevalence abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blastocyst Retrieval Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major adverse cardiac and cerebrovascular event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline level of independence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Irritable Bowel Syndrome Symptom Severity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Profile of Mood States 2nd Edition (POMS 2)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Eyes With ≤ 0.25 Diopter Absolute Refractive Cylinder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scale of self-reported pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fear and anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reduction of arrhythmic relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the serum hGH concentration-time curve (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum observed serum hGH concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area under the effect (IGF-I) curve from time 0 to the time of the last concentration (AUEC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum IGF-I effect (Emax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in colonic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in sodium excretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in absolute body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Exercise Time Trial Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caspase 2 Enzyme Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caspase 3 Enzyme Level, an Average of 3 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caspase 7 Enzyme Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interlukin-10 (IL-10) Serum Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Insulin Growth Factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in eosinophil numbers in submucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in airway wall area percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics (AUC and Ctrough) of Efavirenz 400mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood loss of 500 ml or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinical Response (Complete Response + Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analogue scales
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment Non-adherence Percentage
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Limb rescue rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CMax (Maximum Concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Late loss measured by quantitative coronary angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NIH volume as measured by intravascular ultrasound (IVUS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Volumetric plaque burden as measured by IVUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain as rated by numerical rating scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-Day Survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With craniotomy-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Composite Dysphagia Outcome Determined by PEG Tube Dependence at Last Follow-Up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Dysphagia Outcome Determined by Diagnosis of Aspiration Pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Anti-tumor Effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety and Systemic Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Pathologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean change in trough FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Immune response measured by RRV-specific neutralizing titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of subjects with a RRV-specific neutralizing titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Absence of thromboembolic events
Endpoint domain: Adverse events/effects
Primary endpoint: MSD Influenza A Test Results Against Cell Culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes